The field of endocrinology has lost a remarkable figure with the passing of Joel Habener, MD, on December 28, 2025, at the age of 88. As a professor of medicine at Harvard Medical School and the director of the Laboratory of Molecular Endocrinology at Massachusetts General Hospital in Boston, Habener made significant strides in the understanding and treatment of metabolic diseases. His work was particularly influential in the development of GLP-1-based therapies, which have reshaped the management of type 2 diabetes and obesity.
Joel Habener developed a fascination with glucagon's role in blood sugar regulation during the 1970s, leading to transformative discoveries. Notably, he cloned the glucagon gene, revealing it encodes not only glucagon but also glucagon-like peptide-1 (GLP-1). As described by his colleague, Daniel J. Drucker, MD, this work laid the groundwork for GLP-1 biology, marking an important milestone in molecular endocrinology. This foundational science has since changed the landscape of clinical medicine and understanding of multiple metabolic disorders.
Habener’s discovery of GLP-1 was particularly groundbreaking, as it unveiled new pathways for managing diabetes and obesity through pharmacological interventions. This insight was pivotal enough that drugs developed from this line of research, such as Ozempic and Wegovy, became among the top treatments for these conditions.
Apart from his scientific contributions, Habener was renowned for his mentorship. He cultivated an environment in his lab that welcomed postdoctoral fellows trained in clinical medicine, often providing their first immersion into basic research. This nurturing approach has left a lasting impact, as many of his former trainees have themselves made significant contributions to endocrinology.
His achievements were recognized with countless accolades, including the prestigious Breakthrough Prize for Life Science in 2025, often referred to as the "Oscars of Science," for his role in advancing GLP-1 receptor agonists (GLP-1RAs). Furthermore, in 2024, he received the Lasker~DeBakey Clinical Medical Research Award, validating the clinical significance of his work on glucagon-like peptides.
Habener's pivotal research continued to garner accolades globally. Along with Drucker and Jens Juul Holst, MD, he received the Warren Alpert Foundation Prize for their contributions to understanding gut hormones and their role in metabolism. This recognition marked a significant moment for endocrinology, showcasing how clinical investigation directly leads to therapeutic innovations.
Research led by Habener, Drucker, and Holst has improved the therapeutic landscape and provided insights into various metabolic syndromes, which often include diabetes and obesity. Their collaborative efforts illuminated the pathways linking gut hormones to metabolic diseases, leading to the generation of new drug classes.
Beyond his research, Habener's legacy is characterized by the profound impact of his discoveries on public health. As emphasized by George Q. Daley, MD, PhD, dean of the Faculty of Medicine at Harvard, Habener’s career spanned decades of innovation that reverberated through healthcare. His quest for understanding and solutions for complex metabolic disorders will resonate in the medical community for years to come.
Habener’s vision to explore therapeutic targets, stemming from his work since his early days at the National Institutes of Health, showcases his relentless pursuit of knowledge. He was a firm believer in the potential of recombinant DNA technology to unlock groundbreaking discoveries in medicine.
Joel Habener will be remembered not only for his scientific innovations but also as a mentor who shaped the careers of countless endocrinologists. His insights into glucagon and its related peptides fundamentally changed the approach to treating metabolic diseases, underscoring the need for integrated research and patient care. As the medical community continues to benefit from his work, the enduring legacy of Joel Habener will undoubtedly influence future generations in the field of endocrinology.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.